NL1010018C2 - Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking. - Google Patents

Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking. Download PDF

Info

Publication number
NL1010018C2
NL1010018C2 NL1010018A NL1010018A NL1010018C2 NL 1010018 C2 NL1010018 C2 NL 1010018C2 NL 1010018 A NL1010018 A NL 1010018A NL 1010018 A NL1010018 A NL 1010018A NL 1010018 C2 NL1010018 C2 NL 1010018C2
Authority
NL
Netherlands
Prior art keywords
alkyl
formula
ethyl
group
compound
Prior art date
Application number
NL1010018A
Other languages
English (en)
Dutch (nl)
Inventor
Jacobus Antonius Joseph Hartog
Martinus Theodorus Maria Tulp
Eric Ronken
Gerben Maria Visser
Gerrit Paul Toorop
Johannes Wilhelmus Cath Jansen
Jan Hendrik Reinders
Original Assignee
Duphar Int Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar Int Res filed Critical Duphar Int Res
Application granted granted Critical
Publication of NL1010018C2 publication Critical patent/NL1010018C2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NL1010018A 1997-09-09 1998-09-04 Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking. NL1010018C2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97202762 1997-09-09
EP97202762 1997-09-09

Publications (1)

Publication Number Publication Date
NL1010018C2 true NL1010018C2 (nl) 1999-03-10

Family

ID=8228716

Family Applications (1)

Application Number Title Priority Date Filing Date
NL1010018A NL1010018C2 (nl) 1997-09-09 1998-09-04 Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.

Country Status (9)

Country Link
US (1) US6350750B1 (fr)
EP (1) EP0966442B1 (fr)
JP (1) JP4276703B2 (fr)
AT (1) ATE348812T1 (fr)
AU (1) AU9624198A (fr)
CA (1) CA2270777C (fr)
DE (1) DE69836678T2 (fr)
NL (1) NL1010018C2 (fr)
WO (1) WO1999012908A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE250035T1 (de) * 1997-04-22 2003-10-15 Janssen Pharmaceutica Nv Chinolin- und chinazolin-derivate als crf antagonisten
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
DE60026155T2 (de) 1999-09-30 2006-08-10 Neurogen Corp., Branford Einige alkylendiamin-substituierte heterocyclen
WO2001062718A1 (fr) * 2000-02-25 2001-08-30 Japan Tobacco, Inc. Dérivé de benzamide et utilisation de celui-ci
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AU2004257267B2 (en) * 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
EP1656145A1 (fr) * 2003-08-12 2006-05-17 F. Hoffmann-La Roche Ag Tetrahydroquinazolines spiro-substituees utilisees en tant qu'antagonistes du facteur de liberation de la corticotrophine (crf)
CN100398524C (zh) * 2003-08-12 2008-07-02 弗·哈夫曼-拉罗切有限公司 作为crf拮抗剂的四氢喹唑啉衍生物
WO2011094008A1 (fr) 2010-01-27 2011-08-04 Arena Pharmaceuticals, Inc. Procédés de préparation d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclopenta]indol-3-yl) acétique et de ses sels
EP2619198A1 (fr) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement des troubles qui lui sont liés
EP4445956A2 (fr) 2015-01-06 2024-10-16 Arena Pharmaceuticals, Inc. Composé pour le traitement des affections associés à s1p1-récepteur
WO2016209809A1 (fr) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
WO2018151873A1 (fr) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Composés et méthodes de traitement de l'angiocholite biliaire primitive
EP3601267A1 (fr) 2017-03-21 2020-02-05 Bayer Pharma Aktiengesellschaft 2-méthyl-quinazolines
EP3781565A1 (fr) 2018-04-18 2021-02-24 Bayer Pharma Aktiengesellschaft 2-méthyl-aza-quinazolines
EP4223761A1 (fr) * 2020-09-30 2023-08-09 Shanghai Pharmaceuticals Holding Co., Ltd. Composé quinazoline et son application
CN117203207A (zh) * 2021-04-30 2023-12-08 江苏恒瑞医药股份有限公司 桥环类化合物、其制备方法及其在医药上的应用
CN115504932B (zh) * 2022-08-12 2024-01-26 河南师范大学 一种3-取代喹啉类化合物的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ287613B6 (en) * 1994-06-16 2001-01-17 Pfizer Pyrazolo- and pyrrolopyridines and pharmaceutical preparations based thereon
PL191271B1 (pl) 1996-02-07 2006-04-28 Neurocrine Biosciences Inc Pochodna pirazolopirymidyny i jej zastosowanie oraz kompozycja farmaceutyczna
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
WO1998029397A1 (fr) 1996-12-27 1998-07-09 Yoshitomi Pharmaceutical Industries, Ltd. Composes pyrimidine a anneaux condenses et leur utilisation medicinale
WO1998035967A2 (fr) * 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Antagonistes de recepteurs du crf et procedes associes
ATE250035T1 (de) * 1997-04-22 2003-10-15 Janssen Pharmaceutica Nv Chinolin- und chinazolin-derivate als crf antagonisten

Also Published As

Publication number Publication date
CA2270777A1 (fr) 1999-03-18
JP2001505226A (ja) 2001-04-17
EP0966442B1 (fr) 2006-12-20
ATE348812T1 (de) 2007-01-15
AU9624198A (en) 1999-03-29
WO1999012908A1 (fr) 1999-03-18
DE69836678T2 (de) 2007-04-05
US6350750B1 (en) 2002-02-26
CA2270777C (fr) 2008-04-22
DE69836678D1 (de) 2007-02-01
EP0966442A1 (fr) 1999-12-29
JP4276703B2 (ja) 2009-06-10

Similar Documents

Publication Publication Date Title
NL1010018C2 (nl) Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
KR102366670B1 (ko) O-아미노헤테로아릴알키닐기를 함유한 화합물 및 이의 제조 방법과 용도
KR100256707B1 (ko) 데아자푸린 유도체; 새로운 부류의 crf1 특이 리간드
CN1315809C (zh) 喹啉衍生物和其作为5-ht6配体的用途
KR0173172B1 (ko) Crf 길항제로서의 피롤로피리미딘
US8299092B2 (en) Derivatives of 2-phenyl-3-hydroxyquinoline-4(1H)-one and methods of their preparation and utilization
AU2010202009A1 (en) Quinoxaline compounds
IL125076A (en) Aza compounds, diazole cycloheptane and converted cyclooctane compounds and pharmaceutical preparations containing them
FI100530B (fi) Menetelmä substituoitujen diaminoftaali-imidien ja niiden analogien va lmistamiseksi
TWI781607B (zh) 一種免疫抑制劑、其製備方法和應用
JPH0232058A (ja) 4―アミノ―3―カルボキシキノリン類およびナフチリジン類、製法および医薬用途
JP4199668B2 (ja) Sst1アンタゴニスト活性を有するピペラジン誘導体
EP0650964A1 (fr) Dérivés de 1- 2H-1-benzopyran-2-one-8-yl -pipérazine
Snyder et al. Synthesis of 4-Hydroxyquinolines. VIII. Some Halogen Containing 4-Aminoquinoline Derivatives1
DeWald et al. Synthesis and Potential Antipsychotic Activity of 1H-Imidazo [1, 2-c] pyrazolo [3, 4-e] pyrimidines
EP0093521B1 (fr) Dérivés de la quinoléine
US5804685A (en) Deazapurine derivatives: a new class of CRF1 specific ligands
JPS5838277A (ja) スピロチアゾリジニルピペラジン誘導体
CS202069B2 (en) Method of preparing 2-/4-substituted piperazine-1-yl/-4-amino-6,7-dimethoxyquinazolines
JP4477010B2 (ja) タンパク質チロシンホスファターゼ阻害剤としてのジアミノピロロキナゾリン化合物
JPS6229585A (ja) エーテル化若しくはエステル化しうるジヒドロキシ基により位置2で置換された4―ohキノリンカルボン酸の新規の誘導体、その製造方法、及び医薬としてのその使用
CN105209461A (zh) 咪唑并吡啶衍生物
Nasr et al. Synthesis of pyrimido [5, 4-c] quinolines and related quinolines as potential antimalarials
CN117486782A (zh) 一种n-取代咔唑衍生物及其制备方法和应用
CN115340499A (zh) Bcl-xl抑制剂及其用途

Legal Events

Date Code Title Description
PD2A A request for search or an international type search has been filed
VD1 Lapsed due to non-payment of the annual fee

Effective date: 20090401